focus -WSS

focus

author：leisure time 2025-09-27 09:47:00 - browse：38584

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： STAT Virtual Event: Putting AI to the Test

explore

WSS

With psoriasis trial ahead, Alumis raises $259 million

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Why are Kaiser Permanente staff considering a strike?

Former medical device CEO who sold dummy, plastic parts convicted of fraud

CDC's new outbreak response network to include Northeastern

Biotech stock slump in 2023: awaiting the turnaround

hotspot

focus

knowledge

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

The cancer drug shortage isn’t new — and neither are the solutions

Readout LOUD podcast: possible new ALS drug, artificial wombs

Novavax promises a turnaround & Lilly roils the obesity market

IVF, abortion rights issues kick off Biden’s State of the Union

In age of alternative facts, a scholarly course on calling out crap

Novo Nordisk obesity pill bests Wegovy in early trial

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

leisure time

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Ukraine and a new approach to mental health in war

Drug for rare kidney disease narrowly misses mark in clinical trial

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Senators: Long

hotspot

explore

hotspot

focus